The peptide research blog

Most retatrutide coverage focuses on clinical outcomes — weight loss percentages, FDA timelines, dosing schedules. But the real breakthrough happened years earlier, in controlled lab environments where researchers isolated the compound's molecular behavior.

Retatrutide pharmacology studies reveal triple-receptor GIP/GLP-1/glucagon agonism produces 24% body weight reduction at 48 weeks—mechanisms, trials, and

Retatrutide long term studies show sustained 24%+ weight loss at 48 weeks, with ongoing Phase 3 trials tracking metabolic outcomes through 2028 and beyond.

Retatrutide safety studies haven't revealed the dealbreaker most pharmaceutical watchers expected. The triple-agonist peptide cleared Phase 2 with gastrointestinal side effects comparable to semaglutide and tirzepatide — but without the pancreatitis signal or gallbladder events that haunted earlier GLP-1 trials.

Retatrutide isn't just another GLP-1 agonist — it's the first triple receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously. Early comparative data suggests it outperforms both semaglutide and tirzepatide in weight reduction and metabolic markers.

The most compelling evidence from the cagrilintide study isn't just the weight loss numbers — it's the mechanism. By targeting both GLP-1 and amylin receptors simultaneously, cagrilintide activates complementary satiety pathways that operate independently, creating appetite suppression that doesn't rely on a single hormonal axis.

Top cagrilintide studies show dual amylin-calcitonin agonism produces 10–15% body weight reductions in Phase 2 trials — mechanisms and findings explained.

Cagrilintide isn't just another weight-loss peptide — preclinical animal research demonstrates it activates the calcitonin receptor (CALCR) with a 24-hour half-life, producing sustained satiety signalling that semaglutide alone doesn't replicate. When combined with GLP-1 agonists in primate models, it produces 15–20% body weight reduction — more than either compound achieves independently.

Cagrilintide in vitro research reveals dual amylin receptor agonism that delays gastric emptying and reduces food intake. See the mechanisms and current

Cagrilintide dose response research shows peak efficacy at 2.4mg weekly, reducing weight by 10–12% in Phase 2 trials—what this means for dual agonist

Cagrilintide long term studies show sustained weight loss and glycemic control over 68 weeks with GLP-1/amylin dual agonism mechanisms.

Cagrilintide safety studies show 25–30% nausea rates during titration, with dual-agonist trials demonstrating superior tolerability versus GLP-1

Most weight-loss peptides work through GLP-1 pathways — cagrilintide doesn't. It targets amylin receptors instead, producing gastric delay that lasts longer than any GLP-1 agonist currently approved. Clinical trials show mean weight reductions of 15.6% at 32 weeks when combined with semaglutide.

The survodutide study isn't just another GLP-1 trial — it's the first dual-agonist candidate to demonstrate weight loss results that exceed semaglutide in head-to-head comparison. Phase 2 data published in The Lancet showed 18.6% mean body weight reduction at 48 weeks — a threshold no GLP-1-only medication has crossed in a comparable trial period.

Survodutide isn't semaglutide with a new label — it's a dual-agonist peptide targeting both GLP-1 and glucagon receptors, and the evidence from Phase 2 trials shows metabolic effects that exceed single-pathway treatments. Early results demonstrate 12.5% mean body weight reduction at 48 weeks alongside meaningful liver fat reduction and glycemic control improvements.

Survodutide doesn't just suppress appetite — it rewires how the liver, adipose tissue, and muscle cells metabolise stored energy. Animal studies show a mechanism no single-agonist GLP-1 compound has replicated.

Survodutide in vitro research shows dual GLP-1/glucagon agonism improves hepatic lipid metabolism and β-cell function — here’s what lab models reveal

Survodutide pharmacology studies reveal dual GLP-1/glucagon receptor agonism drives 15-20% weight reduction and metabolic improvements. Phase 3 data shows

Most survodutide dose response research overlooks a critical finding — the therapeutic window isn't linear. Higher doses don't just amplify benefits — they shift which metabolic pathways dominate the response.

Phase 2 survodutide safety studies show GI events in 40–55% of patients, but 89% reach target dose. What the latest trials reveal about dual-agonist

Most weight-loss medications show dramatic results in the first six months, then plateau or regress. Survodutide breaks that pattern — Phase 2 data published in JAMA demonstrates sustained efficacy at 72 weeks with no attenuation of effect.

Survodutide demonstrates dual GLP-1/glucagon receptor agonism with superior weight loss versus semaglutide in head-to-head trials — MASH outcomes remain

Survodutide doesn't work like other GLP-1 medications — it activates two distinct pathways simultaneously. While semaglutide and tirzepatide target satiety alone, survodutide mechanism studies show it combines GLP-1 receptor activation with glucagon receptor agonism to trigger hepatic fat oxidation directly. That's why Phase 2 trials demonstrated 15.

Mazdutide study data reveals dual GLP-1/glucagon receptor agonism delivers 20.6% mean weight loss in 48 weeks with significant metabolic improvements.

Mazdutide demonstrates 20.2% weight reduction in phase 2 trials with dual GLP-1/glucagon receptor activation — clinical data reveals metabolic mechanisms

Mazdutide animal research reveals potent dual GLP-1/glucagon agonism driving 30-40% body weight reduction in rodents — mechanisms, dosage findings, and

Mazdutide dose response research demonstrates 15–25% weight reduction at higher doses. Phase 2 trials reveal optimal titration schedules and metabolic

Phase 2/3 mazdutide trials show 12–24% weight loss with manageable GI side effects. Here’s what the clinical safety data reveals about this dual-agonist

Mazdutide isn't just another GLP-1 drug — it's a dual-agonist peptide activating both GLP-1 and glucagon receptors simultaneously, a mechanism no approved obesity medication currently uses. Early mazdutide pharmacology studies show weight reductions exceeding 20% at 24 weeks alongside metabolic benefits that single-receptor drugs can't replicate.

Mazdutide doesn't just activate GLP-1 receptors — it simultaneously engages glucagon pathways, creating a dual metabolic effect that most single-agonist compounds miss. Lab studies show this combination triggers distinct cellular responses that conventional models can't replicate, which is why in vitro work on mazdutide requires specific receptor assays and precise control systems.

Mazdutide comparative studies don't exist in a vacuum — they're structured to pit one biological mechanism against another. The peptide activates both GLP-1 and glucagon receptors simultaneously, which is mechanistically different from semaglutide's single-target approach. This dual-pathway activation drives metabolic outcomes that can't be replicated by stacking two separate compounds.

Mazdutide doesn't just suppress appetite — it burns energy. Unlike single-target GLP-1 agonists, mazdutide activates both GLP-1 and glucagon receptors simultaneously, creating a metabolic profile that combines satiety signaling with thermogenic fat oxidation. This dual mechanism is what positions it as a next-generation metabolic compound in current phase 3 trials.

The orforglipron study results aren't just about weight loss percentages — they represent the first oral, non-peptide GLP-1 receptor agonist to reach Phase 3 trials with injectable-level efficacy. What makes this compound different isn't the receptor it targets but the delivery mechanism that bypasses first-pass hepatic metabolism entirely.

The top orforglipron studies published through early 2026 aren't just incremental progress — they represent a structural shift in GLP-1 accessibility. Unlike injectable semaglutide or tirzepatide, orforglipron is an oral daily tablet that bypasses first-pass hepatic degradation while maintaining therapeutic GLP-1 receptor activation.

The most surprising finding from orforglipron animal research isn't the weight loss magnitude — it's the dose-dependent glucose control achieved without hypoglycemia. Preclinical studies show mechanistic differences from injectable GLP-1 agonists that matter for human translation.

Orforglipron in vitro research reveals nonpeptide GLP-1R agonism with unique subcellular trafficking profiles — see what lab models show about mechanism

Orforglipron dose response research shows nonlinear efficacy peaks at 36mg daily with weight loss plateaus beyond 45mg — our analysis covers trial data

Orforglipron isn't just another GLP-1 candidate — it's the first non-peptide oral molecule to achieve receptor activation comparable to injectable semaglutide. Phase 2 trials published in NEJM show 15–20% mean body weight reduction without subcutaneous administration.

Orforglipron long term studies reveal sustained weight loss and metabolic improvements over 36 weeks with continued phase 3 data collection underway

Orforglipron safety studies show 30–45% nausea rates during dose escalation, with serious adverse events under 2%. Phase 3 trial results, hepatotoxicity

Orforglipron isn't just another GLP-1 agonist — it's the first daily oral non-peptide option delivering weight loss outcomes within 3% of injectable semaglutide. Head-to-head trials show 14.7% mean body weight reduction at 26 weeks versus 11.5% for semaglutide, with gastrointestinal side effects occurring 22% less frequently.

Tesofensine study data shows 10.6% weight loss at 0.5mg daily vs 2% placebo across 24 weeks — the mechanism targets three monoamine pathways

Orforglipron mechanism studies reveal oral GLP-1 delivery via reversible covalent binding, bypassing injection-dependent peptide degradation pathways

Tesofensine animal research shows triple monoamine reuptake inhibition drives 15–20% weight reduction in rodent models with central appetite suppression.

Top tesofensine studies from Phase 2b and Phase 3 trials show 10.6–12.8% body weight reduction with dopamine-norepinephrine-serotonin reuptake inhibition.

Tesofensine in vitro research reveals triple monoamine reuptake inhibition with potent dopaminergic effects — here’s what lab models show about its

Tesofensine long term studies show sustained weight loss over 6–12 months with modest side effects — but gaps in cardiovascular and metabolic safety data

Phase 2 clinical trials show tesofensine caused dose-dependent adverse events including increased heart rate, dry mouth, and hypertension — here’s the

Tesofensine dose response research shows 0.5mg daily produces 12.8% weight reduction vs placebo at 24 weeks — neurochemical reuptake inhibition mechanism

Tesofensine pharmacology studies show triple monoamine reuptake inhibition drives weight loss through norepinephrine, dopamine, and serotonin pathways —

5-Amino-1MQ study data shows NNMT inhibition triggers fat oxidation. Clinical research, dosing protocols, and mechanisms explained with real trial

Most people assume 5-amino-1MQ is just another weight loss compound. The research tells a different story. The compound's mechanism — NNMT inhibition — triggers mitochondrial changes that affect NAD+ metabolism at a cellular level, with implications that extend far beyond fat reduction.

Tesofensine isn't another GLP-1 analog — it's a triple monoamine reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin breakdown simultaneously. Remove any one pathway and the weight loss effect collapses by 60% or more.

Tesofensine comparative studies reveal 9.2% weight loss vs 1.8% placebo at 24 weeks, outperforming liraglutide and topiramate with sustained appetite

5-amino-1mq animal research shows NNMT inhibition reduces fat mass in rodents by 25–35%. Learn mechanisms, lab protocols, and clinical translation

5-amino-1MQ dose response research shows 50–100mg daily triggers NNMT inhibition in adipocytes, altering NAD+ metabolism and thermogenic signaling in

Most discussions of 5-amino-1MQ focus on weight loss — but the pharmacology studies reveal something more precise. This compound doesn't suppress appetite or mimic GLP-1. It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that regulates NAD+ availability and metabolic flux at the cellular level.

Clinical data on 5-amino-1MQ spans weeks, not years. Review existing safety evidence, mechanistic concerns, and what researchers still don’t know about

5-amino-1MQ inhibits NNMT in cell culture models, increasing NAD+ and shifting cellular metabolism toward fat oxidation. Lab-grade reagent for metabolic

Published trials show 5-amino-1MQ reduced body weight in animal models without severe toxicity, but human safety data remains limited as of 2026.